Seeking Alpha

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering...

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering Lovaza eliminates a key upside opportunity, adding that the extent of the impact on growth is unclear at this point. The firm maintains its Neutral rating on the shares.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs